Group 1 - Moderna (NASDAQ: MRNA) shares have decreased over 35% year-to-date and over 80% on a one-year basis, with a decline of 94% since reaching a pandemic-era high of over $450 per share [1] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts to watch, buy and sell ratings, product sales forecasts, and integrated financial statements [2] Group 2 - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies in the biotech, healthcare, and pharma sectors [2]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Moderna(MRNA.O)上涨1.9%，美国食品药品监督管理局（FDA）批准该公司面向65岁及以上成人的下 一代新冠疫苗。 ...

智通财经6月2日电，美国食品药品监督管理局（FDA）批准Moderna公司新一代新冠疫苗后，Moderna 公司股价上涨7.1%。 ...

Moderna(MRNA.O)盘前上涨4.3%，此前美国食品药品监督管理局（FDA）批准该公司面向65岁及以上 成人的下一代新冠疫苗。 ...

Group 1 - Moderna has received FDA approval for its COVID-19 vaccine MNEXSPIKE [1]

Company Overview - Moderna is focused on building a diverse portfolio of products utilizing mRNA technology, targeting areas such as infectious diseases, cancer, rare diseases, and autoimmune diseases [3]. Strategic Priorities - The company has outlined three main priorities for the year: 1. To drive sales through approved products, specifically COVID-19 and RSV vaccines [3]. 2. To launch new products to diversify and grow the top line, with up to 10 launches planned over the next few years and several Biologics License Applications (BLAs) already filed [4]. 3. To resize the company from a cost perspective in response to the transition from pandemic-related sales [4].

Core Viewpoint - The U.S. government has terminated its contract with Moderna for the late-stage development of an mRNA-based bird flu vaccine, impacting the company's funding and development plans [1][2]. Group 1: Contract and Funding - The Biden administration had awarded Moderna two contracts totaling $766 million, including $590 million for advancing vaccine development and $176 million to expedite vaccine development [2]. - The termination of the contract was anticipated due to a review of agreements made during the Biden administration by the Trump administration [3]. Group 2: Clinical Data and Future Plans - Despite the funding setback, Moderna reported positive interim data from a phase I/II study of its mRNA-1018 vaccine, showing an increase in protective antibody levels from 2.1% to 97.8% after the second dose among 300 participants [4]. - The company plans to present further clinical findings at an upcoming scientific conference and is exploring new paths for pandemic preparedness in light of the funding loss [5]. Group 3: Stock Performance and Market Sentiment - Year-to-date, Moderna's stock has decreased by 37%, contrasting with a 5% decline in the industry [6]. - Negative sentiment surrounding Moderna's stock has been exacerbated by recent FDA guidance limiting COVID-19 booster eligibility and the voluntary withdrawal of a regulatory filing for its COVID-19/influenza vaccine [8][9]. - The company is also working to reduce operating expenses and streamline its R&D pipeline amid these challenges [10].

Financial Data and Key Metrics Changes - The company achieved a 20% cost reduction in Q1 2025 compared to Q1 2024, with a target of around $4 billion in cash costs by 2027, down from $9 billion two years ago [7][6][8] Business Line Data and Key Metrics Changes - The company is focusing on driving sales from its two approved products, COVID and RSV, while planning up to 10 new product launches in the coming years [6][5] - The company is reducing its manufacturing footprint and resizing its operations across all lines of the P&L [8][7] Market Data and Key Metrics Changes - The U.S. COVID vaccine market for the 2024-2025 season was around 40 million doses, with a potential increase in demand for high-risk populations [21][20] - The company is also expanding its sales outside the U.S., with contracts in Canada, the UK, and Australia expected to contribute significantly starting this year [59][60] Company Strategy and Development Direction - The company aims to stabilize its COVID and RSV business while diversifying its product portfolio, including a focus on oncology and autoimmune diseases [5][61] - The strategy includes leveraging existing infrastructure for new product launches to minimize costs [8][7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for increased COVID vaccine demand among high-risk populations, which could lead to a larger market than previously anticipated [23][20] - The company is closely monitoring regulatory changes and their potential impacts on its business, particularly regarding the FDA and CDC [15][17] Other Important Information - The company is experiencing a shift in the regulatory landscape, with the FDA potentially taking a more active role in product recommendations [39][41] - Recent comments from the HHS director regarding mRNA technology have raised concerns, but management emphasized the extensive testing and safety of their products [42][44] Q&A Session Summary Question: How does the company view the impact of regulatory changes on its business? - Management noted that the company does not rely on PBMs for vaccine sales, which insulates it from potential PBM reforms [13] - The company is not significantly impacted by Medicaid reforms, as its primary business is with Medicare [15] Question: What is the company's strategy for the upcoming flu and COVID combo vaccine? - The company is adjusting its filing strategy to include efficacy data for the flu component, which may affect the timing of the launch [72][74] Question: How does the company plan to manage risks associated with its revenue generation? - Management indicated that the guidance for revenue does not include new product launches, which could provide upside if successful [70][71]

Financial Data and Key Metrics Changes - The company reported just under $5 billion in cash on the balance sheet as of March 31, 2025, with no debt [11][35] - The net cash usage for the quarter was approximately $150 million, which is considered a normal quarter for the business [35] - The company has repurchased $1.3 billion of its own stock, reducing the share count by nearly 15% [11][35] Business Line Data and Key Metrics Changes - The company is focused on multiple late-stage pipeline products, including brevacitinib and IMG1402, with significant clinical execution and progress across all main clinical franchises [7][8] - Brevacitinib is expected to be a market therapy within the next couple of years, with pivotal studies ongoing in multiple indications [8][12] - The company has initiated studies in dermatomyositis and cutaneous sarcoidosis, with data readouts expected in the near future [14][18] Market Data and Key Metrics Changes - The company is addressing a patient population with high unmet needs, particularly in dermatomyositis, where the only approved therapy is IVIG [40] - The estimated market for dermatomyositis is between 40,000 to 70,000 patients in the U.S., with approximately 34,000 currently treated [100] Company Strategy and Development Direction - The company aims to capitalize on its strong cash position to drive profitability and pipeline expansion, with $2 billion reserved for future opportunities [11][12] - The focus is on indications with high unmet needs and potential for first-in-class therapies, particularly in the FcRn space [19][88] - The company is preparing for a busy data generation period over the next 36 months, with multiple potential blockbuster launches anticipated [10][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming data readouts and the potential for significant market opportunities, particularly in immunology [10][31] - The company acknowledges the challenging market environment but feels well-positioned compared to peers [12][35] - Management emphasized the importance of capital allocation and the strategic focus on high unmet medical needs [11][12] Other Important Information - The company is in the summary judgment phase of its LNP litigation against Moderna and Pfizer, with a trial expected to follow [32][34] - The company is also awaiting a ruling in the Pfizer case, which is anticipated later this year [51] Q&A Session Summary Question: What are the expectations for the DM study? - Management indicated that a positive study with statistically significant separation from placebo is necessary for success in the DM study [39][40] Question: Can you provide an update on the LNP litigation against Moderna? - Management noted that narrowing the case is a normal part of patent litigation and that parameters will be evident in the near future [43][44] Question: What is the status of the pending Pfizer Markman decision? - Management stated that the timing of the Markman decision is at the judge's discretion and is hopeful for a ruling later this year [51] Question: How is the company planning to position Brevacitinib if approved? - Management views the entire market as addressable and believes many patients represent low-hanging fruit due to the lack of options [60] Question: What are the expectations for the placebo response in the DM study? - Management referenced published data from similar studies that showed a well-behaved placebo response, which is encouraging [70] Question: What is the observable population for dermatomyositis in the U.S.? - Management estimates the DM market to be between 40,000 to 70,000 patients, with around 34,000 currently treated [100]